| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | structural constituent of postsynaptic actin cytoskeleton | 2.26e-06 | 11 | 49 | 3 | GO:0098973 | |
| GeneOntologyMolecularFunction | nucleosomal DNA binding | 2.19e-05 | 67 | 49 | 4 | GO:0031492 | |
| GeneOntologyMolecularFunction | structural molecule activity | 5.01e-05 | 891 | 49 | 10 | GO:0005198 | |
| GeneOntologyMolecularFunction | structural constituent of postsynapse | 6.55e-05 | 32 | 49 | 3 | GO:0099186 | |
| GeneOntologyMolecularFunction | nucleosome binding | 9.76e-05 | 98 | 49 | 4 | GO:0031491 | |
| GeneOntologyMolecularFunction | structural constituent of chromatin | 1.06e-04 | 100 | 49 | 4 | GO:0030527 | |
| GeneOntologyMolecularFunction | structural constituent of synapse | 1.49e-04 | 42 | 49 | 3 | GO:0098918 | |
| GeneOntologyMolecularFunction | structural constituent of cytoskeleton | 2.90e-04 | 130 | 49 | 4 | GO:0005200 | |
| GeneOntologyMolecularFunction | Hsp70 protein binding | 4.97e-04 | 63 | 49 | 3 | GO:0030544 | |
| GeneOntologyMolecularFunction | D-glucose binding | 5.27e-04 | 14 | 49 | 2 | GO:0005536 | |
| GeneOntologyMolecularFunction | chromatin DNA binding | 7.46e-04 | 167 | 49 | 4 | GO:0031490 | |
| GeneOntologyMolecularFunction | AMP binding | 1.20e-03 | 21 | 49 | 2 | GO:0016208 | |
| GeneOntologyMolecularFunction | monosaccharide binding | 1.64e-03 | 95 | 49 | 3 | GO:0048029 | |
| GeneOntologyBiologicalProcess | regulation of DNA recombination | 1.28e-06 | 150 | 48 | 6 | GO:0000018 | |
| GeneOntologyBiologicalProcess | DNA recombination | 1.93e-06 | 368 | 48 | 8 | GO:0006310 | |
| GeneOntologyBiologicalProcess | chromosome condensation | 4.66e-06 | 48 | 48 | 4 | GO:0030261 | |
| GeneOntologyBiologicalProcess | negative regulation of DNA recombination | 8.07e-06 | 55 | 48 | 4 | GO:0045910 | |
| GeneOntologyBiologicalProcess | nucleosome assembly | 9.31e-06 | 122 | 48 | 5 | GO:0006334 | |
| GeneOntologyBiologicalProcess | nucleosome organization | 1.94e-05 | 142 | 48 | 5 | GO:0034728 | |
| GeneOntologyBiologicalProcess | postsynaptic actin cytoskeleton organization | 5.08e-05 | 31 | 48 | 3 | GO:0098974 | |
| GeneOntologyBiologicalProcess | postsynaptic cytoskeleton organization | 7.35e-05 | 35 | 48 | 3 | GO:0099188 | |
| GeneOntologyBiologicalProcess | postsynapse organization | 8.35e-05 | 313 | 48 | 6 | GO:0099173 | |
| GeneOntologyBiologicalProcess | DNA topological change | 2.36e-04 | 10 | 48 | 2 | GO:0006265 | |
| GeneOntologyBiologicalProcess | protein-DNA complex assembly | 2.76e-04 | 249 | 48 | 5 | GO:0065004 | |
| GeneOntologyBiologicalProcess | chromatin remodeling | 2.82e-04 | 741 | 48 | 8 | GO:0006338 | |
| GeneOntologyCellularComponent | euchromatin | 2.64e-05 | 72 | 50 | 4 | GO:0000791 | |
| GeneOntologyCellularComponent | NuA4 histone acetyltransferase complex | 6.08e-05 | 32 | 50 | 3 | GO:0035267 | |
| GeneOntologyCellularComponent | H4/H2A histone acetyltransferase complex | 6.08e-05 | 32 | 50 | 3 | GO:0043189 | |
| GeneOntologyCellularComponent | H4 histone acetyltransferase complex | 1.70e-04 | 45 | 50 | 3 | GO:1902562 | |
| GeneOntologyCellularComponent | nucleosome | 3.31e-04 | 138 | 50 | 4 | GO:0000786 | |
| GeneOntologyCellularComponent | actin filament | 4.10e-04 | 146 | 50 | 4 | GO:0005884 | |
| GeneOntologyCellularComponent | dynein axonemal particle | 1.04e-03 | 20 | 50 | 2 | GO:0120293 | |
| GeneOntologyCellularComponent | histone acetyltransferase complex | 1.48e-03 | 94 | 50 | 3 | GO:0000123 | |
| GeneOntologyCellularComponent | protein acetyltransferase complex | 1.98e-03 | 104 | 50 | 3 | GO:0031248 | |
| GeneOntologyCellularComponent | acetyltransferase complex | 2.26e-03 | 109 | 50 | 3 | GO:1902493 | |
| GeneOntologyCellularComponent | actin cytoskeleton | 2.42e-03 | 576 | 50 | 6 | GO:0015629 | |
| Domain | Histone_H5 | 3.16e-09 | 8 | 50 | 4 | IPR005819 | |
| Domain | H15 | 3.19e-08 | 13 | 50 | 4 | SM00526 | |
| Domain | H15 | 3.19e-08 | 13 | 50 | 4 | PS51504 | |
| Domain | Linker_histone | 3.19e-08 | 13 | 50 | 4 | PF00538 | |
| Domain | Histone_H1/H5_H15 | 4.46e-08 | 14 | 50 | 4 | IPR005818 | |
| Domain | ANK | 3.14e-07 | 251 | 50 | 8 | SM00248 | |
| Domain | ANK_REPEAT | 3.33e-07 | 253 | 50 | 8 | PS50088 | |
| Domain | ANK_REP_REGION | 3.44e-07 | 254 | 50 | 8 | PS50297 | |
| Domain | Ankyrin_rpt | 4.35e-07 | 262 | 50 | 8 | IPR002110 | |
| Domain | Ank_2 | 1.59e-06 | 215 | 50 | 7 | PF12796 | |
| Domain | Ank | 2.36e-06 | 228 | 50 | 7 | PF00023 | |
| Domain | - | 4.11e-06 | 248 | 50 | 7 | 1.25.40.20 | |
| Domain | Ankyrin_rpt-contain_dom | 4.80e-06 | 254 | 50 | 7 | IPR020683 | |
| Domain | Actin_CS | 9.86e-06 | 16 | 50 | 3 | IPR004001 | |
| Domain | ACTINS_2 | 1.20e-05 | 17 | 50 | 3 | PS00432 | |
| Domain | Actin/actin-like_CS | 1.43e-05 | 18 | 50 | 3 | IPR020902 | |
| Domain | ACTINS_ACT_LIKE | 1.70e-05 | 19 | 50 | 3 | PS01132 | |
| Domain | Actin | 7.70e-05 | 31 | 50 | 3 | IPR004000 | |
| Domain | Actin | 7.70e-05 | 31 | 50 | 3 | PF00022 | |
| Domain | ACTIN | 7.70e-05 | 31 | 50 | 3 | SM00268 | |
| Domain | TPR-contain_dom | 6.91e-04 | 150 | 50 | 4 | IPR013026 | |
| Domain | TPR | 9.86e-04 | 165 | 50 | 4 | PS50005 | |
| Domain | TPR_REGION | 9.86e-04 | 165 | 50 | 4 | PS50293 | |
| Domain | TPR_1 | 1.80e-03 | 90 | 50 | 3 | PF00515 | |
| Domain | TPR_1 | 1.80e-03 | 90 | 50 | 3 | IPR001440 | |
| Domain | - | 2.27e-03 | 207 | 50 | 4 | 1.25.40.10 | |
| Domain | - | 2.73e-03 | 218 | 50 | 4 | 1.10.10.10 | |
| Domain | TPR-like_helical_dom | 3.47e-03 | 233 | 50 | 4 | IPR011990 | |
| Domain | WHTH_DNA-bd_dom | 3.97e-03 | 242 | 50 | 4 | IPR011991 | |
| Domain | TPR | 4.98e-03 | 129 | 50 | 3 | SM00028 | |
| Domain | TPR_repeat | 5.42e-03 | 133 | 50 | 3 | IPR019734 | |
| Domain | ER_TARGET | 7.03e-03 | 47 | 50 | 2 | PS00014 | |
| Domain | DnaJ | 7.32e-03 | 48 | 50 | 2 | PF00226 | |
| Domain | DnaJ | 7.62e-03 | 49 | 50 | 2 | SM00271 | |
| Domain | DNAJ_1 | 7.62e-03 | 49 | 50 | 2 | PS00636 | |
| Domain | DNAJ_2 | 7.62e-03 | 49 | 50 | 2 | PS50076 | |
| Domain | - | 7.62e-03 | 49 | 50 | 2 | 1.10.287.110 | |
| Domain | TPR_2 | 7.93e-03 | 50 | 50 | 2 | PF07719 | |
| Domain | TPR_2 | 7.93e-03 | 50 | 50 | 2 | IPR013105 | |
| Domain | DnaJ_domain | 8.24e-03 | 51 | 50 | 2 | IPR001623 | |
| Domain | TPR_8 | 8.87e-03 | 53 | 50 | 2 | PF13181 | |
| Pathway | REACTOME_APOPTOSIS_INDUCED_DNA_FRAGMENTATION | 2.52e-08 | 13 | 36 | 4 | M1018 | |
| Pathway | REACTOME_APOPTOSIS_INDUCED_DNA_FRAGMENTATION | 3.31e-06 | 12 | 36 | 3 | MM14554 | |
| Pathway | REACTOME_APOPTOTIC_EXECUTION_PHASE | 8.89e-06 | 52 | 36 | 4 | M2341 | |
| Pathway | REACTOME_FORMATION_OF_SENESCENCE_ASSOCIATED_HETEROCHROMATIN_FOCI_SAHF | 1.01e-05 | 17 | 36 | 3 | M27189 | |
| Pathway | REACTOME_APOPTOSIS | 8.55e-05 | 179 | 36 | 5 | M15303 | |
| Pathway | REACTOME_PROGRAMMED_CELL_DEATH | 1.85e-04 | 211 | 36 | 5 | M27436 | |
| Pathway | BIOCARTA_FEEDER_PATHWAY | 2.26e-04 | 9 | 36 | 2 | M3061 | |
| Pathway | REACTOME_APOPTOTIC_EXECUTION_PHASE | 2.60e-04 | 49 | 36 | 3 | MM15448 | |
| Pubmed | POTEE ZC3H7A ILF3 HK1 DNAJC10 CTR9 POTEF H1-2 H1-3 H1-4 H1-6 HMGB2 POTEI NEB SKI CTTN DNAH8 ABCB1 | 6.03e-13 | 1442 | 50 | 18 | 35575683 | |
| Pubmed | Identification of a novel actin isoform in hepatocellular carcinoma. | 1.48e-11 | 15 | 50 | 5 | 16824795 | |
| Pubmed | 5.66e-11 | 6 | 50 | 4 | 15562002 | ||
| Pubmed | 1.32e-10 | 7 | 50 | 4 | 15276201 | ||
| Pubmed | All known human H1 histone genes except the H1(0) gene are clustered on chromosome 6. | 1.32e-10 | 7 | 50 | 4 | 8325638 | |
| Pubmed | 4.74e-10 | 9 | 50 | 4 | 16364570 | ||
| Pubmed | High-throughput kinase assays with protein substrates using fluorescent polymer superquenching. | 7.88e-10 | 10 | 50 | 4 | 15927069 | |
| Pubmed | Role of H1 linker histones in mammalian development and stem cell differentiation. | 1.24e-09 | 11 | 50 | 4 | 26689747 | |
| Pubmed | A unified phylogeny-based nomenclature for histone variants. | 1.85e-09 | 12 | 50 | 4 | 22650316 | |
| Pubmed | 2.68e-09 | 13 | 50 | 4 | 8858344 | ||
| Pubmed | 2.80e-09 | 3 | 50 | 3 | 26209608 | ||
| Pubmed | High-resolution mapping of h1 linker histone variants in embryonic stem cells. | 2.80e-09 | 3 | 50 | 3 | 23633960 | |
| Pubmed | 2.80e-09 | 3 | 50 | 3 | 21245380 | ||
| Pubmed | Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. | 3.18e-09 | 256 | 50 | 8 | 24189400 | |
| Pubmed | 3.68e-09 | 163 | 50 | 7 | 24316575 | ||
| Pubmed | POTEE ILF3 DNAJC10 DNAJC8 CTR9 POTEF H1-2 H1-3 H1-4 H1-6 GEMIN5 HMGB2 POTEI | 6.20e-09 | 1153 | 50 | 13 | 29845934 | |
| Pubmed | H1 linker histones are essential for mouse development and affect nucleosome spacing in vivo. | 1.12e-08 | 4 | 50 | 3 | 12808097 | |
| Pubmed | 1.12e-08 | 4 | 50 | 3 | 11746507 | ||
| Pubmed | 1.12e-08 | 4 | 50 | 3 | 10997781 | ||
| Pubmed | 1.12e-08 | 4 | 50 | 3 | 11689686 | ||
| Pubmed | 1.50e-08 | 451 | 50 | 9 | 36168627 | ||
| Pubmed | 2.52e-08 | 334 | 50 | 8 | 30425250 | ||
| Pubmed | Two-Dimensional Fractionation Method for Proteome-Wide Cross-Linking Mass Spectrometry Analysis. | ILF3 HK1 DNAJC8 WNT5A H1-2 H1-3 H1-4 CKAP5 GEMIN5 HMGB2 CTTN | 2.63e-08 | 847 | 50 | 11 | 35235311 |
| Pubmed | The mouse histone H1 genes: gene organization and differential regulation. | 2.79e-08 | 5 | 50 | 3 | 9300059 | |
| Pubmed | 2.79e-08 | 5 | 50 | 3 | 11467742 | ||
| Pubmed | A proposal for a coherent mammalian histone H1 nomenclature correlated with amino acid sequences. | 2.79e-08 | 5 | 50 | 3 | 8003976 | |
| Pubmed | Characterization of the histone H1-binding protein, NASP, as a cell cycle-regulated somatic protein. | 2.79e-08 | 5 | 50 | 3 | 10893414 | |
| Pubmed | Expression of murine H1 histone genes during postnatal development. | 2.79e-08 | 5 | 50 | 3 | 9655912 | |
| Pubmed | ILF3 HK1 YKT6 DNAJC10 POTEF RBM10 LRPAP1 NUP93 SUCLA2 DNAH8 WDR48 | 3.04e-08 | 859 | 50 | 11 | 31536960 | |
| Pubmed | Complementary proteomics strategies capture an ataxin-1 interactome in Neuro-2a cells. | 3.15e-08 | 665 | 50 | 10 | 30457570 | |
| Pubmed | Expanding the Interactome of TES by Exploiting TES Modules with Different Subcellular Localizations. | 4.59e-08 | 235 | 50 | 7 | 28378594 | |
| Pubmed | Characterization of phosphorylation sites on histone H1 isoforms by tandem mass spectrometry. | 5.57e-08 | 6 | 50 | 3 | 15595731 | |
| Pubmed | The multifunctional protein nucleophosmin (NPM1) is a human linker histone H1 chaperone. | 5.57e-08 | 6 | 50 | 3 | 21425800 | |
| Pubmed | Hormone-mediated dephosphorylation of specific histone H1 isoforms. | 5.57e-08 | 6 | 50 | 3 | 11479299 | |
| Pubmed | 5.57e-08 | 6 | 50 | 3 | 17171436 | ||
| Pubmed | Linker histone transitions during mammalian oogenesis and embryogenesis. | 5.57e-08 | 6 | 50 | 3 | 9499577 | |
| Pubmed | Histone H1 recruitment by CHD8 is essential for suppression of the Wnt-β-catenin signaling pathway. | 5.57e-08 | 6 | 50 | 3 | 22083958 | |
| Pubmed | H1 family histones in the nucleus. Control of binding and localization by the C-terminal domain. | 5.57e-08 | 6 | 50 | 3 | 15911621 | |
| Pubmed | 5.93e-08 | 244 | 50 | 7 | 29884807 | ||
| Pubmed | 9.75e-08 | 7 | 50 | 3 | 24435047 | ||
| Pubmed | Histone h1 depletion impairs embryonic stem cell differentiation. | 1.56e-07 | 8 | 50 | 3 | 22589736 | |
| Pubmed | 1.56e-07 | 8 | 50 | 3 | 12475935 | ||
| Pubmed | 2.11e-07 | 441 | 50 | 8 | 31239290 | ||
| Pubmed | H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. | PWWP2A ILF3 CTR9 RBM10 H1-2 H1-4 PAXIP1 CKAP5 H1-6 NUP93 SKI TOP3A | 2.19e-07 | 1294 | 50 | 12 | 30804502 |
| Pubmed | BAP1 regulation of the key adaptor protein NCoR1 is critical for γ-globin gene repression. | ILF3 CTR9 H1-2 H1-3 H1-4 H1-6 GEMIN5 PYGL MTFP1 STIP1 NUP93 SUCLA2 | 2.67e-07 | 1318 | 50 | 12 | 30463901 |
| Pubmed | 3.06e-07 | 463 | 50 | 8 | 34901782 | ||
| Pubmed | Dynamic changes in H1 subtype composition during epigenetic reprogramming. | 3.33e-07 | 10 | 50 | 3 | 28794128 | |
| Pubmed | 3.78e-07 | 660 | 50 | 9 | 32780723 | ||
| Pubmed | Tumor suppressor BAP1 nuclear import is governed by transportin-1. | ILF3 HK1 RBM10 H1-2 CKAP5 GEMIN5 PYGL HMGB2 STIP1 NUP93 CTTN | 5.59e-07 | 1149 | 50 | 11 | 35446349 |
| Pubmed | C9orf72 protein quality control by UBR5-mediated heterotypic ubiquitin chains. | ILF3 HK1 DNAJC10 CTR9 H1-2 H1-3 H1-4 PYGL NUP93 SUCLA2 WDR48 | 1.35e-06 | 1257 | 50 | 11 | 37317656 |
| Pubmed | Systematic Analysis of Human Protein Phosphatase Interactions and Dynamics. | 1.51e-06 | 573 | 50 | 8 | 28330616 | |
| Pubmed | 1.55e-06 | 16 | 50 | 3 | 33288900 | ||
| Pubmed | 1.62e-06 | 251 | 50 | 6 | 31076518 | ||
| Pubmed | 1.73e-06 | 403 | 50 | 7 | 30562941 | ||
| Pubmed | 2.03e-06 | 2 | 50 | 2 | 24873882 | ||
| Pubmed | Structure and expression of the mouse testicular H1 histone gene (H1t). | 2.03e-06 | 2 | 50 | 2 | 8241275 | |
| Pubmed | A primate-specific POTE-actin fusion protein plays a role in apoptosis. | 2.03e-06 | 2 | 50 | 2 | 19669888 | |
| Pubmed | 2.03e-06 | 2 | 50 | 2 | 8867811 | ||
| Pubmed | SARS-CoV-2 uses Spike glycoprotein to control the host's anaerobic metabolism by inhibiting LDHB. | 2.32e-06 | 607 | 50 | 8 | 39147351 | |
| Pubmed | Network organization of the huntingtin proteomic interactome in mammalian brain. | 2.74e-06 | 621 | 50 | 8 | 22794259 | |
| Pubmed | 2.87e-06 | 844 | 50 | 9 | 25963833 | ||
| Pubmed | Reciprocal interaction between SIRT6 and APC/C regulates genomic stability. | 3.09e-06 | 440 | 50 | 7 | 34244565 | |
| Pubmed | 3.20e-06 | 1103 | 50 | 10 | 34189442 | ||
| Pubmed | 3.34e-06 | 638 | 50 | 8 | 33239621 | ||
| Pubmed | 4.04e-06 | 74 | 50 | 4 | 36180920 | ||
| Pubmed | Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation. | ILF3 HK1 DNAJC8 CTR9 H1-2 CKAP5 GEMIN5 STIP1 NUP93 CTTN SUCLA2 | 4.50e-06 | 1425 | 50 | 11 | 30948266 |
| Pubmed | CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma. | 4.63e-06 | 468 | 50 | 7 | 36042349 | |
| Pubmed | 4.73e-06 | 77 | 50 | 4 | 12408966 | ||
| Pubmed | A high-throughput approach for measuring temporal changes in the interactome. | HK1 DNAJC8 CTR9 H1-2 H1-4 GEMIN5 PYGL HMGB2 PSMD5 STIP1 CTTN | 5.49e-06 | 1455 | 50 | 11 | 22863883 |
| Pubmed | 6.07e-06 | 3 | 50 | 2 | 2613692 | ||
| Pubmed | 6.07e-06 | 3 | 50 | 2 | 30568170 | ||
| Pubmed | 6.07e-06 | 3 | 50 | 2 | 24525734 | ||
| Pubmed | Testis-specific expression of the rat histone Hlt gene in transgenic mice. | 6.07e-06 | 3 | 50 | 2 | 7612613 | |
| Pubmed | 6.07e-06 | 3 | 50 | 2 | 18056081 | ||
| Pubmed | Evolution and expression of chimeric POTE-actin genes in the human genome. | 6.07e-06 | 3 | 50 | 2 | 17101985 | |
| Pubmed | 6.07e-06 | 3 | 50 | 2 | 25401518 | ||
| Pubmed | 6.59e-06 | 494 | 50 | 7 | 26831064 | ||
| Pubmed | Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis. | 6.70e-06 | 84 | 50 | 4 | 19135240 | |
| Pubmed | 7.40e-06 | 327 | 50 | 6 | 31409639 | ||
| Pubmed | 7.42e-06 | 187 | 50 | 5 | 26460568 | ||
| Pubmed | 9.24e-06 | 340 | 50 | 6 | 24332808 | ||
| Pubmed | 1.09e-05 | 95 | 50 | 4 | 33863777 | ||
| Pubmed | 1.21e-05 | 4 | 50 | 2 | 19072710 | ||
| Pubmed | Isolation of two murine H1 histone genes and chromosomal mapping of the H1 gene complement. | 1.21e-05 | 4 | 50 | 2 | 8589518 | |
| Pubmed | 1.21e-05 | 4 | 50 | 2 | 17342726 | ||
| Pubmed | 1.26e-05 | 1014 | 50 | 9 | 32416067 | ||
| Pubmed | Human histone gene organization: nonregular arrangement within a large cluster. | 1.77e-05 | 35 | 50 | 3 | 9119399 | |
| Pubmed | FAF1 phosphorylation by AKT accumulates TGF-β type II receptor and drives breast cancer metastasis. | 1.77e-05 | 224 | 50 | 5 | 28443643 | |
| Pubmed | 1.81e-05 | 383 | 50 | 6 | 29331416 | ||
| Pubmed | Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis. | 1.84e-05 | 807 | 50 | 8 | 30575818 | |
| Pubmed | Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. | 1.91e-05 | 1353 | 50 | 10 | 29467282 | |
| Pubmed | 2.02e-05 | 5 | 50 | 2 | 15159385 | ||
| Pubmed | Proteome-wide identification of HSP70/HSC70 chaperone clients in human cells. | 2.08e-05 | 1367 | 50 | 10 | 32687490 | |
| Pubmed | Nuclear High Mobility Group A2 (HMGA2) Interactome Revealed by Biotin Proximity Labeling. | 2.10e-05 | 37 | 50 | 3 | 36835656 | |
| Pubmed | Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate. | 2.40e-05 | 116 | 50 | 4 | 27576135 | |
| Pubmed | 2.67e-05 | 244 | 50 | 5 | 30349055 | ||
| Pubmed | Upregulation of RIN3 induces endosomal dysfunction in Alzheimer's disease. | 2.96e-05 | 418 | 50 | 6 | 32552912 | |
| Pubmed | 3.02e-05 | 123 | 50 | 4 | 35583604 | ||
| Pubmed | 3.08e-05 | 1431 | 50 | 10 | 37142655 | ||
| Pubmed | 3.31e-05 | 43 | 50 | 3 | 22701719 | ||
| Interaction | POTEC interactions | 9.70e-11 | 13 | 50 | 5 | int:POTEC | |
| Interaction | POTEB3 interactions | 2.35e-08 | 35 | 50 | 5 | int:POTEB3 | |
| Interaction | POTED interactions | 5.74e-08 | 4 | 50 | 3 | int:POTED | |
| Interaction | H2AC18 interactions | 7.66e-08 | 148 | 50 | 7 | int:H2AC18 | |
| Interaction | TBX1 interactions | 7.79e-08 | 17 | 50 | 4 | int:TBX1 | |
| Interaction | NEB interactions | 1.42e-07 | 97 | 50 | 6 | int:NEB | |
| Interaction | MEPCE interactions | POTEE ILF3 DNAJC8 POTEF H1-2 H1-3 H1-4 CKAP5 H1-6 LRPAP1 POTEI CTTN | 9.06e-07 | 859 | 50 | 12 | int:MEPCE |
| Interaction | H2BC9 interactions | 1.32e-06 | 446 | 50 | 9 | int:H2BC9 | |
| Interaction | H2AC14 interactions | 1.47e-06 | 144 | 50 | 6 | int:H2AC14 | |
| Interaction | ARHGAP24 interactions | 2.67e-06 | 486 | 50 | 9 | int:ARHGAP24 | |
| Interaction | POTEG interactions | 3.11e-06 | 12 | 50 | 3 | int:POTEG | |
| Interaction | SLFN11 interactions | 3.69e-06 | 376 | 50 | 8 | int:SLFN11 | |
| Interaction | IRAK4 interactions | 5.07e-06 | 46 | 50 | 4 | int:IRAK4 | |
| Interaction | POP1 interactions | 5.18e-06 | 277 | 50 | 7 | int:POP1 | |
| Interaction | H1-10 interactions | 5.56e-06 | 280 | 50 | 7 | int:H1-10 | |
| Interaction | NUPR1 interactions | 5.64e-06 | 683 | 50 | 10 | int:NUPR1 | |
| Interaction | ACTG2 interactions | 6.54e-06 | 49 | 50 | 4 | int:ACTG2 | |
| Interaction | H2BC21 interactions | 6.66e-06 | 696 | 50 | 10 | int:H2BC21 | |
| Interaction | EED interactions | PWWP2A ILF3 YKT6 DNAJC10 DNAJC8 H1-2 H1-4 CKAP5 GEMIN5 LRPAP1 HMGB2 PSMD5 NUP93 CTTN | 7.20e-06 | 1445 | 50 | 14 | int:EED |
| Interaction | HMGA1 interactions | 8.16e-06 | 419 | 50 | 8 | int:HMGA1 | |
| Interaction | H3-5 interactions | 9.17e-06 | 114 | 50 | 5 | int:H3-5 | |
| Interaction | LMNA interactions | ILF3 YKT6 DNAJC10 DNAJC8 CTR9 RBM10 H1-2 H1-4 PSMD5 STIP1 NUP93 CTTN SUCLA2 | 1.05e-05 | 1286 | 50 | 13 | int:LMNA |
| Interaction | HEXIM1 interactions | POTEE ILF3 DNAJC10 POTEF H1-2 H1-3 H1-4 H1-6 HMGB2 POTEI CTTN | 1.14e-05 | 913 | 50 | 11 | int:HEXIM1 |
| Interaction | LARP7 interactions | POTEE ILF3 CTR9 POTEF H1-2 H1-3 H1-4 PAXIP1 H1-6 GEMIN5 HMGB2 POTEI | 1.31e-05 | 1113 | 50 | 12 | int:LARP7 |
| Interaction | CKAP5 interactions | 1.38e-05 | 322 | 50 | 7 | int:CKAP5 | |
| Interaction | H2BC12 interactions | 1.38e-05 | 322 | 50 | 7 | int:H2BC12 | |
| Interaction | TES interactions | 1.68e-05 | 332 | 50 | 7 | int:TES | |
| Interaction | ZCRB1 interactions | 2.01e-05 | 134 | 50 | 5 | int:ZCRB1 | |
| Interaction | SF3B4 interactions | 2.03e-05 | 342 | 50 | 7 | int:SF3B4 | |
| Interaction | PPP1R9B interactions | 2.04e-05 | 626 | 50 | 9 | int:PPP1R9B | |
| Interaction | RPS19 interactions | 2.40e-05 | 639 | 50 | 9 | int:RPS19 | |
| Interaction | USP14 interactions | 2.49e-05 | 489 | 50 | 8 | int:USP14 | |
| Interaction | RRM1 interactions | 2.57e-05 | 141 | 50 | 5 | int:RRM1 | |
| Interaction | BAG1 interactions | 2.68e-05 | 494 | 50 | 8 | int:BAG1 | |
| Interaction | AKAP1 interactions | 3.04e-05 | 503 | 50 | 8 | int:AKAP1 | |
| Interaction | GLE1 interactions | 3.46e-05 | 150 | 50 | 5 | int:GLE1 | |
| Interaction | CEBPB interactions | ILF3 HK1 DNAJC8 CTR9 RBM10 H1-2 H1-3 H1-4 PYGL HMGB2 STIP1 NUP93 TOP3A | 3.58e-05 | 1443 | 50 | 13 | int:CEBPB |
| Interaction | H2AC13 interactions | 3.58e-05 | 75 | 50 | 4 | int:H2AC13 | |
| Interaction | SF3B2 interactions | 3.70e-05 | 517 | 50 | 8 | int:SF3B2 | |
| Interaction | TACC2 interactions | 3.97e-05 | 77 | 50 | 4 | int:TACC2 | |
| Interaction | CDK9 interactions | 4.13e-05 | 685 | 50 | 9 | int:CDK9 | |
| Interaction | H2BC4 interactions | 4.21e-05 | 259 | 50 | 6 | int:H2BC4 | |
| Interaction | PSMD14 interactions | 4.23e-05 | 527 | 50 | 8 | int:PSMD14 | |
| Interaction | PRDM15 interactions | 4.61e-05 | 80 | 50 | 4 | int:PRDM15 | |
| Interaction | DKC1 interactions | 4.93e-05 | 393 | 50 | 7 | int:DKC1 | |
| Interaction | H2AC25 interactions | 5.59e-05 | 84 | 50 | 4 | int:H2AC25 | |
| Interaction | YAP1 interactions | POTEE DNAJC10 DNAJC8 POTEF RBM10 H1-4 CKAP5 GEMIN5 STIP1 POTEI CTTN | 6.12e-05 | 1095 | 50 | 11 | int:YAP1 |
| Interaction | H3C1 interactions | 6.12e-05 | 901 | 50 | 10 | int:H3C1 | |
| Interaction | RPS3 interactions | 6.14e-05 | 721 | 50 | 9 | int:RPS3 | |
| Interaction | CCNO interactions | 6.15e-05 | 31 | 50 | 3 | int:CCNO | |
| Interaction | CHMP4B interactions | 6.55e-05 | 727 | 50 | 9 | int:CHMP4B | |
| Interaction | BAP1 interactions | FAT1 ILF3 HK1 RBM10 H1-2 CKAP5 GEMIN5 PYGL HMGB2 STIP1 NUP93 CTTN | 6.71e-05 | 1314 | 50 | 12 | int:BAP1 |
| Interaction | ADAR interactions | 7.29e-05 | 286 | 50 | 6 | int:ADAR | |
| Interaction | MCM5 interactions | 7.49e-05 | 420 | 50 | 7 | int:MCM5 | |
| Interaction | IKZF1 interactions | 7.58e-05 | 288 | 50 | 6 | int:IKZF1 | |
| Interaction | RPS15 interactions | 7.83e-05 | 423 | 50 | 7 | int:RPS15 | |
| Interaction | POU5F1 interactions | 8.70e-05 | 584 | 50 | 8 | int:POU5F1 | |
| Interaction | NOC4L interactions | 8.89e-05 | 183 | 50 | 5 | int:NOC4L | |
| Interaction | SREK1 interactions | 8.89e-05 | 183 | 50 | 5 | int:SREK1 | |
| Interaction | FUS interactions | 8.92e-05 | 757 | 50 | 9 | int:FUS | |
| Interaction | TTN interactions | 9.31e-05 | 299 | 50 | 6 | int:TTN | |
| Interaction | H2AC6 interactions | 1.10e-04 | 100 | 50 | 4 | int:H2AC6 | |
| Interaction | HELLS interactions | 1.11e-04 | 192 | 50 | 5 | int:HELLS | |
| Interaction | TRIM33 interactions | 1.20e-04 | 453 | 50 | 7 | int:TRIM33 | |
| Interaction | KMT2A interactions | 1.22e-04 | 314 | 50 | 6 | int:KMT2A | |
| Interaction | CEP83 interactions | 1.23e-04 | 39 | 50 | 3 | int:CEP83 | |
| Interaction | MAN2C1 interactions | 1.23e-04 | 39 | 50 | 3 | int:MAN2C1 | |
| Interaction | NR2C2 interactions | ILF3 CTR9 H1-2 H1-3 H1-4 H1-6 GEMIN5 PYGL MTFP1 STIP1 NUP93 SUCLA2 | 1.26e-04 | 1403 | 50 | 12 | int:NR2C2 |
| Interaction | HMX2 interactions | 1.26e-04 | 7 | 50 | 2 | int:HMX2 | |
| Interaction | EFCAB12 interactions | 1.26e-04 | 7 | 50 | 2 | int:EFCAB12 | |
| Interaction | H2AC7 interactions | 1.43e-04 | 107 | 50 | 4 | int:H2AC7 | |
| Interaction | DCAF4L2 interactions | 1.43e-04 | 41 | 50 | 3 | int:DCAF4L2 | |
| Interaction | SIRT6 interactions | 1.44e-04 | 628 | 50 | 8 | int:SIRT6 | |
| Interaction | PRP4K interactions | 1.57e-04 | 329 | 50 | 6 | int:PRP4K | |
| Interaction | H3C15 interactions | 1.59e-04 | 207 | 50 | 5 | int:H3C15 | |
| Interaction | PHLPP1 interactions | 1.68e-04 | 333 | 50 | 6 | int:PHLPP1 | |
| Interaction | CIT interactions | ILF3 DNAJC10 POTEM CTR9 RBM10 SPTB H1-2 H1-3 H1-4 CKAP5 H1-6 NUP93 | 1.71e-04 | 1450 | 50 | 12 | int:CIT |
| Interaction | CENPU interactions | 1.77e-04 | 113 | 50 | 4 | int:CENPU | |
| Interaction | RPS17 interactions | 1.79e-04 | 337 | 50 | 6 | int:RPS17 | |
| Interaction | RPS3A interactions | 1.92e-04 | 655 | 50 | 8 | int:RPS3A | |
| Interaction | ATXN1 interactions | 1.98e-04 | 1039 | 50 | 10 | int:ATXN1 | |
| Interaction | BMS1 interactions | 2.02e-04 | 218 | 50 | 5 | int:BMS1 | |
| Interaction | H2AC12 interactions | 2.09e-04 | 118 | 50 | 4 | int:H2AC12 | |
| Interaction | H1-2 interactions | 2.15e-04 | 666 | 50 | 8 | int:H1-2 | |
| Interaction | TAAR3P interactions | 2.15e-04 | 9 | 50 | 2 | int:TAAR3P | |
| Interaction | NSD1 interactions | 2.16e-04 | 119 | 50 | 4 | int:NSD1 | |
| Interaction | U2SURP interactions | 2.16e-04 | 349 | 50 | 6 | int:U2SURP | |
| Interaction | PCBP1 interactions | 2.26e-04 | 671 | 50 | 8 | int:PCBP1 | |
| Interaction | KRI1 interactions | 2.34e-04 | 225 | 50 | 5 | int:KRI1 | |
| Interaction | ZNF668 interactions | 2.38e-04 | 226 | 50 | 5 | int:ZNF668 | |
| Interaction | H1-1 interactions | 2.40e-04 | 507 | 50 | 7 | int:H1-1 | |
| Interaction | POTEF interactions | 2.48e-04 | 228 | 50 | 5 | int:POTEF | |
| Interaction | RSF1 interactions | 2.53e-04 | 124 | 50 | 4 | int:RSF1 | |
| Interaction | RPS20 interactions | 2.57e-04 | 513 | 50 | 7 | int:RPS20 | |
| Interaction | SSRP1 interactions | 2.60e-04 | 685 | 50 | 8 | int:SSRP1 | |
| Interaction | NOP9 interactions | 2.61e-04 | 125 | 50 | 4 | int:NOP9 | |
| Interaction | CHMP4C interactions | 2.65e-04 | 687 | 50 | 8 | int:CHMP4C | |
| Interaction | CTR9 interactions | 2.74e-04 | 233 | 50 | 5 | int:CTR9 | |
| Interaction | TOMM22 interactions | 2.87e-04 | 368 | 50 | 6 | int:TOMM22 | |
| Interaction | TOP1 interactions | 2.89e-04 | 696 | 50 | 8 | int:TOP1 | |
| Cytoband | 2q21.1 | 3.82e-05 | 58 | 51 | 3 | 2q21.1 | |
| Cytoband | 6p21.3 | 1.75e-04 | 250 | 51 | 4 | 6p21.3 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr2q21 | 6.47e-04 | 151 | 51 | 3 | chr2q21 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr6p22 | 8.33e-04 | 378 | 51 | 4 | chr6p22 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr5q33 | 7.69e-03 | 118 | 51 | 2 | chr5q33 | |
| Cytoband | 11q13 | 7.69e-03 | 118 | 51 | 2 | 11q13 | |
| GeneFamily | Ankyrin repeat domain containing|POTE ankyrin domain containing | 1.71e-16 | 13 | 38 | 7 | 685 | |
| GeneFamily | Ankyrin repeat domain containing | 6.25e-07 | 242 | 38 | 7 | 403 | |
| GeneFamily | Tetratricopeptide repeat domain containing|Bardet-Biedl syndrome associated|BBSome | 9.70e-05 | 115 | 38 | 4 | 769 | |
| GeneFamily | Histones | 1.00e-04 | 116 | 38 | 4 | 864 | |
| GeneFamily | DNAJ (HSP40) heat shock proteins|C2 tensin-type domain containing | 4.75e-03 | 49 | 38 | 2 | 584 | |
| Coexpression | ZHAN_MULTIPLE_MYELOMA_UP | 6.84e-06 | 64 | 50 | 4 | M3958 | |
| Coexpression | RAO_BOUND_BY_SALL4_ISOFORM_B | 1.36e-05 | 584 | 50 | 8 | MM1080 | |
| Coexpression | GSE37534_UNTREATED_VS_GW1929_TREATED_CD4_TCELL_PPARG1_AND_FOXP3_TRASDUCED_DN | 3.85e-05 | 199 | 50 | 5 | M8979 | |
| ToppCell | COVID-19_Severe|World / Disease group, lineage and cell class | 9.98e-08 | 197 | 51 | 6 | f0824f98269bdcd8463873beaf222df8f0caa468 | |
| ToppCell | PBMC-Severe|PBMC / Location, Disease Group, Cell group, Cell class (2021.03.09) | 9.98e-08 | 197 | 51 | 6 | af10b5e6e959e2ced01ad066f906941bc4194cc3 | |
| ToppCell | PBMC-Control-Hematopoietic-Platelet-Platelet-plt_5|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 4.92e-07 | 136 | 51 | 5 | 27a41463e6f16deb5b1d4f17fefded9959038c07 | |
| ToppCell | PBMC-Control-Hematopoietic-Platelet-Platelet-plt_5|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.92e-07 | 136 | 51 | 5 | 88b5c839d0446c6d6b7e81fc4d48f5e7e96eea11 | |
| ToppCell | TCGA-Brain-Primary_Tumor-Glioblastoma-Primary_GBM-11|TCGA-Brain / Sample_Type by Project: Shred V9 | 8.30e-07 | 63 | 51 | 4 | d7dc1356a60cb527fe668328d5375f352239d911 | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-hematologic-thrombocytic-platelet|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.96e-06 | 180 | 51 | 5 | beb4d777e0c5fa0a59672dbc3dbb7732498605ff | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-hematologic-thrombocytic|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.96e-06 | 180 | 51 | 5 | fb3d549c2a69b2157a486786ddd775ca16699ed0 | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-hematologic|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.24e-06 | 185 | 51 | 5 | 9f1a790680caaf9c1ec35db5e4b7641497401179 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES-C|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.49e-06 | 189 | 51 | 5 | c502f0cf16fac9f09891d288dcf0149b9eee9d10 | |
| ToppCell | Endothelial-Endothelial-D_(cycle)|Endothelial / shred on cell class and cell subclass (v4) | 2.62e-06 | 191 | 51 | 5 | a3c5a913a99f17633c140ec9ece81b73e59e0715 | |
| ToppCell | COVID-19_Severe|World / Disease condition and Cell class | 2.90e-06 | 195 | 51 | 5 | 22f56ccb81967bff54a1f90e949a8dfc2ce0e4ab | |
| ToppCell | PBMC-Severe|PBMC / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.05e-06 | 197 | 51 | 5 | 3ff23b86d310ace388d2efb3ee73dd47c46f363e | |
| ToppCell | Severe|World / Disease group and Cell class | 3.21e-06 | 199 | 51 | 5 | b73ae402b258fcc17e6cd6d6045244eccfe38ef8 | |
| ToppCell | COVID-19-COVID-19_Severe|COVID-19 / Disease, condition lineage and cell class | 3.28e-06 | 200 | 51 | 5 | 3ec89071f002bb66d46146bf4804f91e6f09a36f | |
| ToppCell | TCGA-Breast-Primary_Tumor-Breast_Carcinoma-Infiltrating_Lobular_Carcinoma-9|TCGA-Breast / Sample_Type by Project: Shred V9 | 3.48e-06 | 90 | 51 | 4 | 96e836c7a1df279ac812b7c3aa75e6b81b614244 | |
| ToppCell | Control-PLT_5|World / Disease Group and Platelet Clusters | 1.32e-05 | 126 | 51 | 4 | 4ba753c4e83eb1d41964edfa22135e047f06c481 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-Mast-Mast-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 5.46e-05 | 181 | 51 | 4 | c35ca98c474e31917e0a53c092397e0d8d18b37c | |
| ToppCell | Lymphoid-Lymphoid-T_cells_(cycle)|Lymphoid / shred on cell class and cell subclass (v4) | 5.46e-05 | 181 | 51 | 4 | b6b41cd5d43543fe7a093033dae52a789199db0e | |
| ToppCell | PND10-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_B-B-B_G2M|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.82e-05 | 184 | 51 | 4 | 8f40093de5bb978f046d66e8f05f333686a009a4 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_NK-NK_dim-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 6.20e-05 | 187 | 51 | 4 | 0bca79cea4886b66350c56c61859bd71e1e7a85c | |
| ToppCell | MatrixFB-Fibroblast-E_(Early_Fibroblastic_progenitor)|MatrixFB / shred on cell class and cell subclass (v4) | 6.33e-05 | 188 | 51 | 4 | b240ea20750ffb825cb5fe41d06c632233406ab6 | |
| ToppCell | Fibroblast-E_(Early_Fibroblastic_progenitor)|World / shred on cell class and cell subclass (v4) | 6.33e-05 | 188 | 51 | 4 | be3db9768364568f44e32ae6b3bf99e49b0978bb | |
| ToppCell | droplet-Marrow-BM_(NON-STC)-30m-Myeloid-granulocytopoietic_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.59e-05 | 190 | 51 | 4 | 4288189e3a499c395896c950598810b02f401685 | |
| ToppCell | Endothelial-D_(cycle)|World / shred on cell class and cell subclass (v4) | 6.73e-05 | 191 | 51 | 4 | 49a4d8f181558e3be9527a8ff9a178f3bb01323c | |
| ToppCell | 3'_v3-bone_marrow|World / Manually curated celltypes from each tissue | 6.73e-05 | 191 | 51 | 4 | 7b759831f1b1c8575c31f67d0d9eb11c6a833cf3 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_mem|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 7.15e-05 | 194 | 51 | 4 | 40c7f9bd69a8e843b81972e25a67f591021415dd | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_mem-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 7.29e-05 | 195 | 51 | 4 | 51e6cfecd66a874673d0b79a295489a358bddfd5 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_cycling-mes_proliferating3_(7)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 7.29e-05 | 195 | 51 | 4 | 1a5e814e12fe37287dbfc58189e1958e2c76b5da | |
| ToppCell | Control-Neu_4|Control / 5 Neutrophil clusters in COVID-19 patients | 7.44e-05 | 196 | 51 | 4 | b8b7b54ca17a08fa775507bb22b1c7248ada8f40 | |
| ToppCell | COVID-19_Severe|World / Disease condition and Cell class | 7.44e-05 | 196 | 51 | 4 | 450ac2aff89c5ca73b8bfbc80663e03be066931f | |
| ToppCell | COVID-19_Severe|World / disease group, cell group and cell class | 7.44e-05 | 196 | 51 | 4 | 3bedf60f662b373ad9d0f07d4da9f11864af3a74 | |
| ToppCell | COVID-19_Severe-NK|World / disease group, cell group and cell class | 7.44e-05 | 196 | 51 | 4 | f46ca7cc2d8407d0dcaa77c4b16a2c1f2a23734d | |
| ToppCell | 3'-Adult-LargeIntestine|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.58e-05 | 197 | 51 | 4 | 03646005921bc330b7a9f66889ef1a7b9a3d530e | |
| ToppCell | severe-unassigned|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 7.58e-05 | 197 | 51 | 4 | 70704b149b2820b8601d2495b7cd9cbe91eda262 | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_B-B_lineage-pre_B_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 7.58e-05 | 197 | 51 | 4 | 106b0f9a0425facc634feb7498c9ba2c55edfbf8 | |
| ToppCell | COVID-19_Severe-NK_activated|World / disease group, cell group and cell class | 7.58e-05 | 197 | 51 | 4 | a60db36d1a192998e3ded63e0c7c08d41689f95f | |
| ToppCell | 3'-Adult-LargeIntestine-Epithelial|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.73e-05 | 198 | 51 | 4 | 2445c9ff8e3f69314bdcb04faf7735272b916242 | |
| ToppCell | 10x_3'_v3-blood_(10x_3'_v3)-lymphocytic-T_lymphocytic-type_I_NK_T_cell|blood_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 7.73e-05 | 198 | 51 | 4 | 58d805e827299292750b09c6283fdbe406b75f79 | |
| ToppCell | 10x_3'_v3-blood_(10x_3'_v3)-lymphocytic-T_lymphocytic-CD8-positive,_alpha-beta_cytokine_secreting_effector_T_cell|blood_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 7.73e-05 | 198 | 51 | 4 | 34c564ece9a2b94dcf646e3c95b5be9c5ecfaafe | |
| ToppCell | Non-neuronal-Dividing-IPC-IPC-div1-28|World / Primary Cells by Cluster | 7.89e-05 | 199 | 51 | 4 | 787688b68ae5d8768c0a24673ae07ab07616764a | |
| ToppCell | 3'-Adult-LargeIntestine-Epithelial-epithelial_progenitor_cell-TA|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.89e-05 | 199 | 51 | 4 | 0649a2c5b8b1f01bb4c4d1eb114cf78a32f8ccd8 | |
| ToppCell | 3'-Adult-LargeIntestine-Epithelial-epithelial_progenitor_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.89e-05 | 199 | 51 | 4 | e3e28981783b922027cee7fe8863386b02c7c758 | |
| ToppCell | Non-neuronal-Dividing-IPC-IPC-div1|World / Primary Cells by Cluster | 7.89e-05 | 199 | 51 | 4 | 72823f26ecabcae1b514b7629cfce010c97b929a | |
| ToppCell | Biopsy_Control_(H.)|World / Sample group, Lineage and Cell type | 7.89e-05 | 199 | 51 | 4 | 254c255292d9810fcea017526eae5ddb3a465ce3 | |
| ToppCell | Non-neuronal-Dividing-IPC-IPC-div2|World / Primary Cells by Cluster | 8.04e-05 | 200 | 51 | 4 | 4923d7a4f00853c4d76fc1cc0fa82d522a2302e7 | |
| ToppCell | PBMC-Severe-cDC_9|Severe / Compartment, Disease Groups and Clusters | 8.04e-05 | 200 | 51 | 4 | ea3b22126d9dfd158bb3c3e1323b30514d721ded | |
| ToppCell | severe|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 8.04e-05 | 200 | 51 | 4 | accc618d6b960bff30cb531c1226295bfc8650f6 | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-2m-Stem_cells-Neuroepithelial_cell|2m / Sample Type, Dataset, Time_group, and Cell type. | 8.04e-05 | 200 | 51 | 4 | 0d9b8d51a7630e70e60c76c763ff82df4c559152 | |
| ToppCell | Non-neuronal-Dividing-IPC-IPC-div2-5|World / Primary Cells by Cluster | 8.04e-05 | 200 | 51 | 4 | dc1c1506823eaa105f1532c6b5d4efa14e788314 | |
| ToppCell | severe-MAIT|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 8.04e-05 | 200 | 51 | 4 | 8a849d0ef244aa2666da2d31bd0731fb04e40911 | |
| ToppCell | COVID-19|World / Disease, condition lineage and cell class | 8.04e-05 | 200 | 51 | 4 | 7dec470c379cd89f05a0f37c8628b21f136e52f0 | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-2m-Stem_cells|2m / Sample Type, Dataset, Time_group, and Cell type. | 8.04e-05 | 200 | 51 | 4 | 0675f580ccef705875854247bbfd4ee2bcf126a1 | |
| ToppCell | severe-NK|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 8.04e-05 | 200 | 51 | 4 | d6767f06fe13be8110a86c2a6029be2dd9ce666c | |
| Drug | belinostat | 7.37e-08 | 50 | 49 | 5 | CID006918638 | |
| Drug | NSC-629231 | 1.20e-07 | 55 | 49 | 5 | CID000363885 | |
| Drug | 3-aminobenzamide | 1.03e-06 | 156 | 49 | 6 | CID000001645 | |
| Drug | 3-tert-butylphenyl-N-methyl-carbamate | 1.06e-06 | 36 | 49 | 4 | CID000013072 | |
| Drug | heparin disaccharide iii-S | 1.19e-06 | 37 | 49 | 4 | CID000448838 | |
| Drug | DNA methyltransferase inhibitor | 1.19e-06 | 160 | 49 | 6 | CID000344265 | |
| Drug | diazinon | 2.19e-06 | 98 | 49 | 5 | CID000003017 | |
| Drug | Spkk | 2.20e-06 | 43 | 49 | 4 | CID000129363 | |
| Drug | GH 5 | 2.64e-06 | 45 | 49 | 4 | CID000163897 | |
| Drug | SN-38 | 2.69e-06 | 184 | 49 | 6 | CID000104842 | |
| Drug | N-myristoyl-rkrtlrrl | 2.89e-06 | 46 | 49 | 4 | CID003081274 | |
| Drug | AC1Q6AQ7 | 3.05e-06 | 188 | 49 | 6 | CID000005515 | |
| Drug | Scriptaid | 3.44e-06 | 48 | 49 | 4 | CID000005186 | |
| Drug | Apicidin | 4.41e-06 | 113 | 49 | 5 | CID000467801 | |
| Drug | CAS 1400-61-9 | 5.13e-06 | 53 | 49 | 4 | CID000004568 | |
| Drug | 5-methyl-dCTP | 5.96e-06 | 55 | 49 | 4 | CID000161376 | |
| Drug | sodium butyrate | 8.42e-06 | 344 | 49 | 7 | CID005222465 | |
| Drug | SK-7041 | 8.45e-06 | 60 | 49 | 4 | CID006918714 | |
| Drug | gold sodium thiomalate | 9.63e-06 | 62 | 49 | 4 | CID000022318 | |
| Drug | chlorambucil | 9.78e-06 | 133 | 49 | 5 | CID000002708 | |
| Drug | Amphoterin | 1.21e-05 | 139 | 49 | 5 | CID003496889 | |
| Drug | F2-b | 1.24e-05 | 66 | 49 | 4 | CID000001700 | |
| Drug | N-bromosuccinimide | 1.48e-05 | 69 | 49 | 4 | CID000067184 | |
| Drug | syntide-2 | 1.65e-05 | 71 | 49 | 4 | CID005074902 | |
| Drug | spermidine | 1.66e-05 | 253 | 49 | 6 | CID000001102 | |
| Drug | NSC351140 | 1.86e-05 | 258 | 49 | 6 | CID000002210 | |
| Drug | spermine | 2.02e-05 | 394 | 49 | 7 | CID000001103 | |
| Drug | AC1Q6SXM | 2.53e-05 | 79 | 49 | 4 | CID000000717 | |
| Drug | Trapoxin B | 2.53e-05 | 79 | 49 | 4 | CID000005532 | |
| Drug | Stallimycin | 2.65e-05 | 80 | 49 | 4 | CID000003115 | |
| Drug | C04378 | 2.93e-05 | 82 | 49 | 4 | CID000440315 | |
| Drug | BM-11 | 2.95e-05 | 28 | 49 | 3 | CID003036083 | |
| Drug | AC1Q5O3Q | 3.29e-05 | 29 | 49 | 3 | CID000368335 | |
| Drug | hydroxyurea | 3.86e-05 | 436 | 49 | 7 | CID000003657 | |
| Drug | glycogen | 4.27e-05 | 443 | 49 | 7 | CID000439177 | |
| Drug | dimethyl 2,3,5,6-tetrachloroterephthalate | 4.52e-05 | 5 | 49 | 2 | ctd:C007220 | |
| Drug | elomotecan | 4.52e-05 | 5 | 49 | 2 | CID000216300 | |
| Drug | LAQ824 | 4.60e-05 | 92 | 49 | 4 | CID006445533 | |
| Drug | 8-bromoguanosine | 4.80e-05 | 93 | 49 | 4 | CID000092977 | |
| Drug | polyarginine | 5.22e-05 | 95 | 49 | 4 | CID000072364 | |
| Drug | AC1L8YYB | 5.35e-05 | 34 | 49 | 3 | CID000435167 | |
| Drug | NSC23766 | 5.89e-05 | 98 | 49 | 4 | CID000409805 | |
| Drug | Metronidazole [443-48-1]; Down 200; 23.4uM; PC3; HG-U133A | 6.30e-05 | 196 | 49 | 5 | 1921_DN | |
| Drug | Azacyclonol [115-46-8]; Down 200; 15uM; HL60; HG-U133A | 6.61e-05 | 198 | 49 | 5 | 2020_DN | |
| Drug | PHA-00767505E [723337-45-9]; Up 200; 10uM; MCF7; HT_HG-U133A | 6.61e-05 | 198 | 49 | 5 | 6596_UP | |
| Drug | YM-4 | 6.77e-05 | 6 | 49 | 2 | CID003081881 | |
| Drug | AC1L45LU | 7.79e-05 | 205 | 49 | 5 | CID000151069 | |
| Drug | S-p-nitrobenzyloxycarbonylglutathione | 8.11e-05 | 39 | 49 | 3 | CID004632704 | |
| Drug | gamma-butyrolactone | 8.61e-05 | 108 | 49 | 4 | CID000007302 | |
| Drug | CGP 41251 | 8.61e-05 | 108 | 49 | 4 | CID000104937 | |
| Drug | LBH589 | 8.92e-05 | 109 | 49 | 4 | CID006918837 | |
| Drug | AlCl3 | 1.03e-04 | 113 | 49 | 4 | CID000024012 | |
| Drug | mustard oil | 1.06e-04 | 114 | 49 | 4 | CID000005971 | |
| Drug | MgCl2 | 1.08e-04 | 354 | 49 | 6 | CID000024584 | |
| Drug | AC1L1FWN | 1.26e-04 | 227 | 49 | 5 | CID000003425 | |
| Drug | NSC-294410 | 1.26e-04 | 8 | 49 | 2 | CID000457914 | |
| Drug | NaBu | 1.38e-04 | 122 | 49 | 4 | CID000052923 | |
| Drug | 5-methylcytosine | 1.42e-04 | 233 | 49 | 5 | CID000065040 | |
| Drug | Velcade (bortezomib | 1.45e-04 | 374 | 49 | 6 | CID000093860 | |
| Drug | Kemptide | 1.47e-04 | 124 | 49 | 4 | CID000100074 | |
| Drug | D03954 | 1.62e-04 | 9 | 49 | 2 | CID009851821 | |
| Drug | alpha-maltosyl fluoride | 1.62e-04 | 9 | 49 | 2 | CID000194237 | |
| Drug | butyrolactone I | 1.66e-04 | 128 | 49 | 4 | CID000123740 | |
| Drug | DADS | 1.81e-04 | 131 | 49 | 4 | CID000016590 | |
| Drug | gossypol | 1.86e-04 | 247 | 49 | 5 | CID000003503 | |
| Drug | Edotecarinum | 2.02e-04 | 10 | 49 | 2 | CID000151078 | |
| Drug | AC1MZ4R5 | 2.02e-04 | 10 | 49 | 2 | CID003842392 | |
| Drug | 32 P | 2.24e-04 | 405 | 49 | 6 | CID000448772 | |
| Drug | MDO-CPT | 2.46e-04 | 11 | 49 | 2 | CID000072403 | |
| Drug | phenylurethane | 2.95e-04 | 12 | 49 | 2 | CID000007591 | |
| Drug | AC1MUW49 | 2.95e-04 | 12 | 49 | 2 | CID003647579 | |
| Drug | NC-190 | 2.95e-04 | 12 | 49 | 2 | CID000129234 | |
| Drug | MS-275 | 2.97e-04 | 149 | 49 | 4 | CID000004261 | |
| Drug | fructose-1,6-diphosphate sodium salt | 3.12e-04 | 151 | 49 | 4 | CID000000718 | |
| Drug | propranolol | 3.24e-04 | 434 | 49 | 6 | CID000004946 | |
| Drug | ara-AC | 3.27e-04 | 279 | 49 | 5 | CID000001805 | |
| Drug | sulfite | 3.40e-04 | 438 | 49 | 6 | CID000001099 | |
| Drug | S 16020-2 | 3.49e-04 | 13 | 49 | 2 | CID000177329 | |
| Drug | AC1NTMU5 | 3.49e-04 | 13 | 49 | 2 | CID003035508 | |
| Drug | Beta-D-Glucose | 3.49e-04 | 13 | 49 | 2 | DB02379 | |
| Drug | phylloerythrin | 3.49e-04 | 13 | 49 | 2 | CID005480977 | |
| Drug | methyl 1'-epiacarviosin | 3.49e-04 | 13 | 49 | 2 | CID000197426 | |
| Drug | glyceraldehyde-3-phosphate | 3.80e-04 | 159 | 49 | 4 | CID000000729 | |
| Drug | DX-8951f | 4.06e-04 | 14 | 49 | 2 | CID000151114 | |
| Drug | CI-937 | 4.06e-04 | 14 | 49 | 2 | CID005364123 | |
| Drug | Pe v | 4.27e-04 | 164 | 49 | 4 | CID005326793 | |
| Drug | gibberellin (GA | 4.47e-04 | 166 | 49 | 4 | CID000006466 | |
| Drug | DB08184 | 4.57e-04 | 167 | 49 | 4 | CID009547945 | |
| Drug | lurtotecan | 4.68e-04 | 15 | 49 | 2 | CID000060955 | |
| Drug | 4-nitrophenylmaltoheptaoside | 4.68e-04 | 15 | 49 | 2 | CID000173254 | |
| Drug | NMHE | 4.68e-04 | 15 | 49 | 2 | CID000042722 | |
| Drug | In-G | 4.89e-04 | 170 | 49 | 4 | CID000446054 | |
| Disease | Robinow syndrome (implicated_via_orthology) | 2.17e-06 | 2 | 44 | 2 | DOID:0060254 (implicated_via_orthology) | |
| Disease | acute lymphoblastic leukemia (is_implicated_in) | 7.69e-05 | 55 | 44 | 3 | DOID:9952 (is_implicated_in) | |
| Disease | Paranoia | 1.19e-04 | 11 | 44 | 2 | C1456784 | |
| Disease | hemoglobin A1 measurement | 1.03e-03 | 520 | 44 | 5 | EFO_0007629 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| YSKKLAEKAVLAANG | 156 | P26439 | |
| ALKKALAAAGYDVEK | 61 | P16403 | |
| NVILAKYGLDGKKDA | 116 | P30533 | |
| AKLYDLAKNADKVLE | 626 | Q8N1F7 | |
| DAGYAILEKKGALAE | 691 | P98175 | |
| DKELLAYAKAGAVAE | 241 | P08183 | |
| LLKAGKAKEVSYNAL | 31 | Q6ZW49 | |
| ALDKDKGKNAEVLYS | 1586 | Q14517 | |
| KALLLYGADIESKNK | 256 | A5A3E0 | |
| EKDIAAYRAKGKSEA | 156 | P26583 | |
| TDDLKALYKVAGADG | 2856 | Q96JB1 | |
| YVLADAIDKGKKAGE | 51 | Q9UDX5 | |
| KAIKKRGDYDANIVA | 191 | P19367 | |
| KALLLYGADIESKNK | 256 | A0JP26 | |
| KALLLYGADIESKNK | 256 | Q6S8J3 | |
| KLEAGDYADLVKALK | 311 | Q14008 | |
| ARAGLIQKDAAKKYD | 106 | Q569G3 | |
| LKKALAAAGYDVEKN | 66 | P22492 | |
| SNKKVAKAYAALAAL | 571 | Q12906 | |
| KKYFLASLDRAKAEA | 471 | Q6PD62 | |
| EAKAAAKREDQKYAL | 116 | Q8WXU2 | |
| AQKAFEAVDKAYKLL | 96 | O75937 | |
| ALKKALAAAGYDVEK | 61 | P10412 | |
| DAKERAAAKDKYQLA | 376 | Q96KS0 | |
| GKKILYDILAFAKES | 436 | Q8IXB1 | |
| AALKKALAAAGYDVE | 61 | P16402 | |
| KDFDARKAYLAGSIK | 146 | Q8TCE6 | |
| TKEYAIKLLAADAGK | 461 | Q9BZA8 | |
| KALLLYGADIESKNK | 256 | B2RU33 | |
| KALLLYGADIESKNK | 256 | Q86YR6 | |
| GLYRKAITEAAKAAK | 726 | Q96N64 | |
| LGNDAYKKKDFDTAL | 231 | P31948 | |
| KALLLYGADIESKNK | 256 | P0CG38 | |
| AYKKESAKEAGAAAV | 46 | P12755 | |
| DEAYAIAKKLGSKDV | 81 | Q9P2R7 | |
| KGEAKVVLLKAAYDV | 11 | O15498 | |
| KALAYAKDKELVASA | 121 | Q8TAF3 | |
| EKAAAKALKEANGYV | 476 | Q96LT9 | |
| KELEEGKAAYLKDGS | 751 | O15394 | |
| DSAAVGFDYKEKLAK | 281 | Q14247 | |
| CAYDAAKVLAKKGDA | 1051 | Q8TEQ6 | |
| KVGDALKEKYDSAAA | 261 | P41221 | |
| GYDLAAVEAAKKKHE | 451 | P11277 | |
| VAKAKKLDEALAQYF | 621 | Q13472 | |
| KALSDLGRYKKAYDA | 131 | Q8IWR0 | |
| ASKDAKYELVKALAN | 451 | Q16401 | |
| IDDVAALDKKGYEAK | 716 | P06737 | |
| KALLLYGADIESKNK | 256 | Q6S5H5 | |
| KALLLYGADIESKNK | 256 | A6NI47 | |
| VAGKAYLEEDKSKAA | 56 | A0A1B0GUJ8 | |
| KAAGDALSDKLYKEN | 376 | P20929 |